This trial is conducted in Europe. The aim of the trial is to investigate different needle features assessed by comparing insulin aspart Pharmacokinetics profiles (the exposure of the trial drug in the body)
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Enrollment
46
All subjects make three intervention visits with at least 5 days between individual intervention visits. At each intervention visit the subject receives one insulin aspart injection with only one type of needle.
Novo Nordisk Investigational Site
Neuss, Germany
Area under curve insulin aspart measured in serum
Time frame: During a maximum of 8 hours
Maximum concentration of insulin aspart measured in serum
Time frame: During a maximum of 8 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.